Literature DB >> 11106944

Adherent dendritic cells expressing high levels of interleukin-10 and low levels of interleukin-12 induce antigen-specific tolerance to experimental autoimmune encephalomyelitis.

J S Yang1, L Y Xu, Y M Huang, P H Van Der Meide, H Link, B G Xiao.   

Abstract

We have previously shown that tolerance can be induced against acute experimental autoimmune encephalomyelitis (EAE) in Lewis rats by bone marrow-derived dendritic cells (DC) that have been pulsed in vitro with encephalitogenic myelin basic protein peptide 68-86 (MBP 68-86), and injected subcutaneously into healthy rats prior to immunization with MBP 68-86 plus complete Freund's adjuvant. To elucidate better the properties of tolerogenic DC, we here compared plastic-adherent DC with floating, non-adherent DC, which were cultured for 7 days in the presence of granulocyte-macrophage colony-stimulating factor plus interleukin-4 (IL-4). Adherent DC expressed high levels of IL-10 mRNA and protein, and low levels of IL-12 mRNA and showed high expression of CD54 compared with floating DC. Proliferation, nitrite concentration and capacity for antigen presentation were lower in adherent DC than in floating DC. There were no differences between adherent and floating DC regarding expression of CD11c, OX62, major histocompatibility complex class II, CD80, or CD86. Most importantly, we observed that adherent DC induced tolerance to EAE in vivo when injected subcutaneously into Lewis rats prior to immunization, while floating DC did not. Adherent DC-mediated tolerance to EAE was associated with augmented proliferation, nitric oxide production and frequency of apoptotic cells as well as with up-regulation of transforming growth factor-beta (TGF-beta) -expressing cells in T-cell areas of lymph nodes. Tolerance induction by adherent DC seems to be related to a nitric oxide-apoptosis pathway and to up-regulation of TGF-beta-expressing cells.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11106944      PMCID: PMC2327087          DOI: 10.1046/j.1365-2567.2000.00115.x

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  33 in total

Review 1.  T-cell priming by type-1 and type-2 polarized dendritic cells: the concept of a third signal.

Authors:  P Kaliński; C M Hilkens; E A Wierenga; M L Kapsenberg
Journal:  Immunol Today       Date:  1999-12

2.  Mechanisms of recovery from experimental allergic encephalomyelitis induced with myelin basic protein peptide 68-86 in Lewis rats: a role for dendritic cells in inducing apoptosis of CD4+ T cells.

Authors:  B G Xiao; Y M Huang; L Y Xu; M Ishikawa; H Link
Journal:  J Neuroimmunol       Date:  1999-06-01       Impact factor: 3.478

3.  CD40-deficient dendritic cells producing interleukin-10, but not interleukin-12, induce T-cell hyporesponsiveness in vitro and prevent acute allograft rejection.

Authors:  J X Gao; J Madrenas; W Zeng; M J Cameron; Z Zhang; J J Wang; R Zhong; D Grant
Journal:  Immunology       Date:  1999-10       Impact factor: 7.397

4.  IFN-gamma plays a critical down-regulatory role in the induction and effector phase of myelin oligodendrocyte glycoprotein-induced autoimmune encephalomyelitis.

Authors:  D O Willenborg; S Fordham; C C Bernard; W B Cowden; I A Ramshaw
Journal:  J Immunol       Date:  1996-10-15       Impact factor: 5.422

5.  Nitric oxide plays a critical role in the recovery of Lewis rats from experimental autoimmune encephalomyelitis and the maintenance of resistance to reinduction.

Authors:  N C O'Brien; B Charlton; W B Cowden; D O Willenborg
Journal:  J Immunol       Date:  1999-12-15       Impact factor: 5.422

6.  IFN-gamma is critical to the control of murine autoimmune encephalomyelitis and regulates both in the periphery and in the target tissue: a possible role for nitric oxide.

Authors:  D O Willenborg; S A Fordham; M A Staykova; I A Ramshaw; W B Cowden
Journal:  J Immunol       Date:  1999-11-15       Impact factor: 5.422

7.  Cellular mRNA expression of interferon-gamma (IFN-gamma), IL-4 and transforming growth factor-beta (TGF-beta) in rats nasally tolerized against experimental autoimmune myasthenia gravis (EAMG).

Authors:  C G Ma; G X Zhang; B G Xiao; H Link
Journal:  Clin Exp Immunol       Date:  1996-06       Impact factor: 4.330

8.  Induction of tolerance by IL-10-treated dendritic cells.

Authors:  K Steinbrink; M Wölfl; H Jonuleit; J Knop; A H Enk
Journal:  J Immunol       Date:  1997-11-15       Impact factor: 5.422

9.  Class I-restricted cross-presentation of exogenous self-antigens leads to deletion of autoreactive CD8(+) T cells.

Authors:  C Kurts; H Kosaka; F R Carbone; J F Miller; W R Heath
Journal:  J Exp Med       Date:  1997-07-21       Impact factor: 14.307

10.  Interleukin-10 induces a long-term antigen-specific anergic state in human CD4+ T cells.

Authors:  H Groux; M Bigler; J E de Vries; M G Roncarolo
Journal:  J Exp Med       Date:  1996-07-01       Impact factor: 14.307

View more
  11 in total

Review 1.  Dendritic cells, T cell tolerance and therapy of adverse immune reactions.

Authors:  P A Morel; M Feili-Hariri; P T Coates; A W Thomson
Journal:  Clin Exp Immunol       Date:  2003-07       Impact factor: 4.330

2.  Mechanisms of apoptosis of T-cells in human tuberculosis.

Authors:  Christina S Hirsch; John L Johnson; Alphonse Okwera; Richard A Kanost; Mianda Wu; Pierre Peters; Mathew Muhumuza; Harriet Mayanja-Kizza; Roy D Mugerwa; Peter Mugyenyi; Jerrold J Ellner; Zahra Toossi
Journal:  J Clin Immunol       Date:  2005-07       Impact factor: 8.317

3.  Tolerance of activated pathogenic CD4+ T cells by transcriptional targeting of dendritic cells.

Authors:  B de Andrade Pereira; M Ackermann; S Chaudhary; R Vogel; B Vogt; C Dresch; C Fraefel
Journal:  Gene Ther       Date:  2015-03-05       Impact factor: 5.250

4.  Binding and transfer of human immunodeficiency virus by DC-SIGN+ cells in human rectal mucosa.

Authors:  Kevin B Gurney; Julie Elliott; Hoorig Nassanian; Carol Song; Elizabeth Soilleux; Ian McGowan; Peter A Anton; Benhur Lee
Journal:  J Virol       Date:  2005-05       Impact factor: 5.103

Review 5.  Potential immunological consequences of pharmacological suppression of gastric acid production in patients with multiple sclerosis.

Authors:  Sangita Biswas; Stephen H Benedict; Sharon G Lynch; Steven M LeVine
Journal:  BMC Med       Date:  2012-06-07       Impact factor: 8.775

6.  A novel method of modifying immune responses by vaccination with lipiodol-siRNA mixtures.

Authors:  Thomas E Ichim; Igor A Popov; Neil H Riordan; Hamid Izadi; Zaohui Zhong; Li Yijian; Salman Sher; Eugenia K Oleinik
Journal:  J Transl Med       Date:  2006-01-03       Impact factor: 5.531

7.  Preventing autoimmune arthritis using antigen-specific immature dendritic cells: a novel tolerogenic vaccine.

Authors:  Igor Popov; Mu Li; Xiufen Zheng; Hongtao San; Xusheng Zhang; Thomas E Ichim; Motohiko Suzuki; Biao Feng; Costin Vladau; Robert Zhong; Bertha Garcia; Gill Strejan; Robert D Inman; Wei-Ping Min
Journal:  Arthritis Res Ther       Date:  2006       Impact factor: 5.156

8.  Repetitive injections of dendritic cells matured with tumor necrosis factor alpha induce antigen-specific protection of mice from autoimmunity.

Authors:  Mauritius Menges; Susanne Rössner; Constanze Voigtländer; Heike Schindler; Nicole A Kukutsch; Christian Bogdan; Klaus Erb; Gerold Schuler; Manfred B Lutz
Journal:  J Exp Med       Date:  2002-01-07       Impact factor: 14.307

9.  Generation of a novel regulatory NK cell subset from peripheral blood CD34+ progenitors promoted by membrane-bound IL-15.

Authors:  Massimo Giuliani; Julien Giron-Michel; Simone Negrini; Paola Vacca; Deniz Durali; Anne Caignard; Caroline Le Bousse-Kerdiles; Salem Chouaib; Aurore Devocelle; Rajia Bahri; Antoine Durrbach; Yassine Taoufik; Silvano Ferrini; Michela Croce; Maria Cristina Mingari; Lorenzo Moretta; Bruno Azzarone
Journal:  PLoS One       Date:  2008-05-21       Impact factor: 3.240

Review 10.  Regulatory dendritic cells for immunotherapy in immunologic diseases.

Authors:  John R Gordon; Yanna Ma; Laura Churchman; Sara A Gordon; Wojciech Dawicki
Journal:  Front Immunol       Date:  2014-01-31       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.